These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3300097

  • 1. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ, Panzig E, Lorenz G, Steinhauser I, Fiedler R.
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [Abstract] [Full Text] [Related]

  • 2. [Liver damage in hormone therapy of prostate cancer].
    Zade W, Schott H.
    Z Urol Nephrol; 1987 Mar; 80(3):177-9. PubMed ID: 3604474
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
    Guddat HM, Schnorr D, Zemke F.
    Z Urol Nephrol; 1987 Mar; 80(3):165-70. PubMed ID: 3300098
    [Abstract] [Full Text] [Related]

  • 10. [Conservative therapy of prostate cancer using Turisteron].
    Schnorr D, Dörner G, Stahl F, Rohde W, Guddat HM.
    Z Urol Nephrol; 1987 Mar; 80(3):149-57. PubMed ID: 3111122
    [Abstract] [Full Text] [Related]

  • 11. The EORTC Phase III trials in prostatic cancer.
    Robinson MR, Smith PH, Macaluso MP, Sylvester R, de Voogt H.
    Prog Clin Biol Res; 1985 Mar; 185A():243-9. PubMed ID: 3898132
    [No Abstract] [Full Text] [Related]

  • 12. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB.
    Prog Clin Biol Res; 1987 Mar; 243B():227-8. PubMed ID: 3116555
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
    Daponte DP, Stevens I, Robinson MR.
    Actas Urol Esp; 1986 Mar; 10(6):437-40. PubMed ID: 3825644
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
    Stridsklev IC, Fosså SD, Kaalhus O.
    Tidsskr Nor Laegeforen; 1984 Oct 10; 104(28):1977-80. PubMed ID: 6388019
    [No Abstract] [Full Text] [Related]

  • 18. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC, Gill GM, Cummings KB.
    Semin Oncol; 1983 Sep 10; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S.
    Prog Clin Biol Res; 1988 Sep 10; 260():111-7. PubMed ID: 2966403
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.